# ARION (durvalumab): what clinicians are saying

> 14 statements from 6 sources (1 video, 5 posts), 5 of them from 3 confirmed clinicians, each linked to its source. Commentary checked Nov 21, 2026.

## Report

- Trial: Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer: a Comparative Randomized Phase II Trial
- NCT ID: NCT03777813
- Registry: https://clinicaltrials.gov/study/NCT03777813
- Sponsor: UNICANCER
- Phase: Phase 2
- Status: Completed
- Drugs tested: durvalumab
- Indication: localised unresectable esophageal cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-11-21 UTC
- Last checked: 2026-11-21 UTC
- Release hash: ada8382fe422a80c6bc75f4d17ce6455489f8b43fc1937f21bd495ba8a778a11

## Counts

- Commentary sources screened: 16
- Sources cited by verified statements: 6
- Verified statements: 14
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 5
- Findings: 5
- Named people in screened sources (unnamed speakers and accounts not counted): 7
- Speakers cited: 7
- Cited speakers with a verified identity: 6
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 3
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 3
- By role and specialty (the abstract's specialty counts):
  - 2 physician, Radiation oncology
  - 1 physician, Gastroenterology

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

The clinicians cited read ARION as negative because reported outcomes did not improve, with one radiation oncologist qualifying that reading by the small, predominantly squamous cohort. That clinician reports frequent severe treatment-related toxicity but no safety signal, and regards the younger-patient survival observation as hypothesis-generating. Differences between numerical accounts remain unexplained. The sources place the phase II results at ESMO 2026.

## Question clinicians left open

What evidence do clinicians say is needed to determine whether adding durvalumab to definitive chemoradiotherapy improves overall survival in patients younger than 65 with localised unresectable oesophageal cancer, beyond ARION’s exploratory findings?

From finding F3 (5 statements from 3 speakers in 3 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. ARION: why speakers see no significant PFS or OS benefit from adding durvalumab
  - 7 statements from 5 speakers in 5 sources, 1 of them a podcast or video.
  - 5 of the 5 named speakers in this finding hold this view.
  - 2 of the report's 3 cited clinicians.
- F2. ARION safety: most speakers see no new signal, but most flag severe toxicity
  - 3 statements from 3 speakers in 3 sources.
  - 2 of the 3 named speakers in this finding hold this view; 2 of the 3 hold its caveat, “most flag severe toxicity”.
  - 1 of the report's 3 cited clinicians.
- F3. Under-65 OS: speakers flag a signal, but a clinician calls it exploratory only
  - 5 statements from 3 speakers in 3 sources.
  - 3 of the 3 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician calls it exploratory only”.
  - 1 of the report's 3 cited clinicians.
- F4. ARION: a clinician views radiation as mostly immunosuppressive
  - 1 statement from 1 speaker in 1 source.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 3 cited clinicians.

### Beyond the trial population

- F5. RT and systemic therapy: a speaker asks about integration across settings
  - 1 statement from 1 speaker in 1 source.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.

1 of the 5 findings and 1 of the 14 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 7 | 5 | 5 | 5 | 3 |
| F2 | 3 | 3 | 3 | 3 | 2 |
| F3 | 5 | 3 | 3 | 3 | 3 |
| F4 | 1 | 1 | 1 | 1 | 1 |
| F5 | 1 | 1 | 1 | 1 | 1 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 4 | 0 | 0 | 1 | 2 | 8 | 0 | 4 posts and articles, 1 podcast or video |
| F2 | 1 | 0 | 0 | 0 | 2 | 3 | 0 | 3 posts and articles |
| F3 | 3 | 0 | 0 | 0 | 2 | 5 | 0 | 3 posts and articles |
| F4 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 post or article |
| F5 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 post or article |

### Trial dimensions

- Primary endpoint: cPFS (centrally reviewed cPFS): F1 (6 shared claims), F3 (1 shared claims)
- Secondary endpoint: Overall survival (OS): F1 (5 shared claims), F2 (2 shared claims), F3 (4 shared claims)
- Secondary endpoint: Adverse Events: F2 (3 shared claims), F3 (2 shared claims)
- Secondary endpoint: Quality of Life OES18, used for patients with oesophageal cancer always complemented by the QLQ-C30 measuring 5 functional scales (physical, everyday activity, cognitive, emotional and social) and 3 symptoms scales (fatigue, pain, nausea and vomiting): no finding draws on it directly
- Population and setting: F1 (5 shared claims), F3 (1 shared claims)
- The comparison: F1 (5 shared claims), F3 (1 shared claims)
- Safety and tolerability: F2 (3 shared claims), F3 (2 shared claims)
- Design and conduct: F1 (3 shared claims), F2 (1 shared claims), F3 (1 shared claims)

## Abbreviations

- ESMO: European Society for Medical Oncology
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- OS: overall survival
- PFS: progression-free survival
- RT: radiotherapy

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 5 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 14 | Paid |
| Who said each statement: the cited speakers | 7 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 3 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 6 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 12 | Free |
| Sources with links | 6 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 3 of the 7 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

11 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: cPFS (centrally reviewed cPFS) | discussed | 6 | 5 |
| Secondary endpoint: Overall survival (OS) | discussed | 8 | 5 |
| Secondary endpoint: Adverse Events | discussed | 3 | 3 |
| Secondary endpoint: Quality of Life OES18, used for patients with oesophageal cancer always complemented by the QLQ-C30 measuring 5 functional scales (physical, everyday activity, cognitive, emotional and social) and 3 symptoms scales (fatigue, pain, nausea and vomiting) | no commentary found | 0 | 0 |
| Population and setting | discussed | 5 | 5 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 5 | 5 |
| Safety and tolerability | discussed | 3 | 3 |
| Design and conduct | discussed | 4 | 3 |
| Younger-patient survival signal and patient-selection research | discussed | 4 | 3 |
| Other negative immunotherapy–chemoradiotherapy studies as interpretive context | discussed | 2 | 2 |
| Radiation's immunological interpretation | discussed | 1 | 1 |
| Cross-setting integration of radiotherapy and systemic treatment | discussed | 1 | 1 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 3 statements · 21%** | | | |
| YouTube | 0 | 0 | 1 |
| X videos | 3 | 1 | 1 |
| **Posts · 11 statements · 79%** | | | |
| X threads | 7 | 3 | 12 |
| LinkedIn posts | 4 | 2 | 2 |

- Screened window: 2026-09-22 to 2026-11-14
- Cited window: 2026-09-30 to 2026-11-14
- Retrieved: 2026-11-20

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer: a Comparative Randomized Phase II Trial
- Also known as: PRODIGE 67
- Registry: NCT03777813 (https://clinicaltrials.gov/study/NCT03777813)
- Study IDs: UC-110/1719 -PRODIGE 67-UCGI33 · 2018-000708-40
- Sponsor: UNICANCER
- Design: Phase 2 · interventional, randomized, parallel, phase2
- Status: Completed
- Enrollment: 112 (actual)
- Start: 2018-12-05 (actual)
- Primary completion: 2024-05-24 (actual)
- Primary endpoint: cPFS (centrally reviewed cPFS) (12-months cPFS)
- Intervention: Durvalumab (drug)
- Intervention: IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU) (combination product)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 11 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 46 sources about other trials or topics are not included; discussion that uses 4 names the trial shares with other things, without the trial's condition or setting, may be missing.
- The sources reviewed for this edition are a limited set of public discussions, not a representative sample of treating clinicians; repeated circulation does not establish independent agreement.
- Discussion without the trial's names or identifiers, or using different wording or transcription variants, may be missing.
- No protocol was listed in the trial's ClinicalTrials.gov record, and no results publication for this exact trial was identified. The report describes attributed accounts rather than independently reconciled efficacy and safety results.
- A speaker's and Martinez another speaker's hazard-ratio summaries differ without an explanation in their statements, so the estimates are not combined.
- The younger-patient survival observation remains a trend or exploratory signal, and the expected value of ancillary studies is prospective.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-21 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-21 UTC. No changes.

## Offer

- Size: Focused · 14 verified statements · 5 from 3 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (6 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/arion-nct03777813
- Agents: POST https://www.erudio.com/api/orders with {"report": "arion-nct03777813", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=arion-nct03777813

## Cite

Erudio Health. ARION (NCT03777813): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 21, 2026. https://www.erudio.com/reports/arion-nct03777813

## Questions

### How much does the ARION report cost?

One edition costs $750 (Focused · 14 verified statements · 5 from 3 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the ARION report cover?

14 statements from 6 sources (1 video, 5 posts), 5 of them from 3 confirmed clinicians, each linked to its source. Commentary checked Nov 21, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the ARION report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "arion-nct03777813" }) previews it and create_order({ "report": "arion-nct03777813", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the ARION report?

Edition 1 (version 1.0.0), accepted Nov 21, 2026 UTC; last checked for new commentary Nov 21, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/arion-nct03777813.json
- Markdown: https://www.erudio.com/reports/arion-nct03777813.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/arion-nct03777813/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "arion-nct03777813"}`
